Illumina and tempus partner to drive the future of precision medicine through genomic ai innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease san diego and chicago , april 15, 2025 /prnewswire/ -- illumina inc. (nasdaq: ilmn) and tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. the collaboration will combine leading illumina ai technologies with tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
TEM Ratings Summary
TEM Quant Ranking